Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain (SENZA-PDN)
A Post-Market, Multicenter, Prospective, Randomized Clinical Trial Comparing 10 kHz Spinal Cord Stimulation (HF10™ Therapy) Combined With Conventional Medical Management to Conventional Medical Management Alone in the Treatment of Chronic, Intractable, Neuropathic Limb Pain
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Bradenton, Florida, United States, 34209
- Coastal Orthopedics
-
-
Georgia
-
Stockbridge, Georgia, United States, 30281
- Georgia Pain Care
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Wisconsin
-
Greenfield, Wisconsin, United States, 53221
- Advanced Pain Management
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have been clinically diagnosed with painful diabetic neuropathy (PDN) of the lower limbs.
- Average pain intensity of ≥ 5 out of 10 cm on the VAS in the lower extremities at enrollment.
- Have stable neurological status.
- Be on a stable analgesic regimen.
- Be 22 years of age or older at the time of enrollment.
- Be an appropriate candidate for the surgical procedures required in this study.
- Be capable of subjective evaluation, able to read and understand English-written questionnaires, and able to read, understand and sign the written informed consent in English.
- Be willing and capable of giving informed consent.
- Be willing and able to comply with study-related requirements, procedures, and scheduled visits.
Exclusion Criteria:
- Have a diagnosis of a lower limb mononeuropathy, have had a lower limb amputation, or have large (≥3 cm) and/or gangrenous ulcers of the lower limbs.
- Have a BMI ≥ 40.
- Currently prescribed a daily opioid dosage > 120 mg morphine equivalents.
- Have a medical condition or pain in other area(s), not intended to be treated in this study.
- Have a current diagnosis of a progressive neurological disease such a multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, central deafferentation syndrome, Complex Regional Pain Syndrome, acute herniating disc, severe spinal stenosis and brachial plexus injury.
- Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, low platelet count, severely diminished functional capacity due to underlying cardiac/pulmonary disease, symptomatic uncontrolled hypertension, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure.
- Have failed prior SCS, dorsal root ganglion (DRG) stimulation, or peripheral nerve stimulation (PNS) trials for chronic intractable pain.
- Have significant spinal stenosis, objective evidence of epidural scarring and/or any signs or symptoms of myelopathy.
- Any previous history of surgery on the posterior elements (laminectomy, posterior fusion) resulting in a compromised epidural space.
- Be benefitting from an interventional procedure and/or surgery to treat lower limb pain.
- Have an existing drug pump and/or another active implantable device such as a pacemaker.
- Have a condition currently requiring or likely to require the use of diathermy or MRI that is inconsistent with Senza system guidelines in the Physician's Manual.
- Have either a metastatic malignant neoplasm or untreated local malignant neoplasm.
- Have a life expectancy of less than one year.
- Have a local infection at the anticipated surgical entry site or an active systemic infection.
- Be pregnant or plan to become pregnant during the study. Women of childbearing potential who are sexually active must use a reliable form of birth control, be surgically sterile, or be at least 2 years post-menopausal.
- Have within 6 months of enrollment a significant untreated addiction to dependency producing medications, alcohol or illicit drugs.
- Be concomitantly participating in another clinical study.
- Be involved in an injury claim under current litigation.
- Be a recipient of Social Security Disability Insurance (SSDI).
- Have a pending or approved worker's compensation claim.
- Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance with intervention and/or ability to evaluate treatment outcome.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: HF10 therapy plus CMM
The addition of HF10 (10kHz SCS) therapy to Conventional Medical Management
|
Senza 10kHz Spinal Cord Stimulation
|
|
Other: CMM Alone
Conventional Medical Management
|
Conventional Medical Management
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite of Safety and Effectiveness
Time Frame: 3 months
|
Difference between treatment groups in responder rates in subjects without a clinically meaningful neurological deficit compared with baseline.
Responder is defined as a subject who has at least 50% reduction in lower limb pain from Baseline as measured by a 10 cm Visual Analog Scale (VAS).
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Scores of 3 or Less
Time Frame: 3 months
|
Difference between the treatment groups in proportion of subjects with a lower limb pain VAS score ≤ 3 cm.
|
3 months
|
|
Crossover Rates
Time Frame: 6 months
|
Difference between the treatment groups in crossover rates.
Subjects who meet pre-specified criteria may elect to crossover to the other treatment arm at 6-month follow-up.
|
6 months
|
|
Responder Rates
Time Frame: 6 months
|
Difference between the treatment groups in responder rates.
Responder is defined as a subject who has at least 50% reduction in lower limb pain from Baseline as measured by a 10 cm Visual Analog Scale (VAS).
|
6 months
|
|
Remitter Rates
Time Frame: 6 months
|
Difference between the treatment groups in the proportion of remitters (remission is defined as having a lower limb pain VAS score of ≤ 3.0 cm for at least 6 months).
|
6 months
|
|
Neurological Assessment
Time Frame: 3 months
|
Difference between the treatment groups in the proportion of subjects with overall improvement from baseline in neurological assessment (motor, sensory, reflex).
|
3 months
|
|
Neurological Assessment
Time Frame: 6 months
|
Difference between the treatment groups in the proportion of subjects with overall improvement from baseline in neurological assessment (motor, sensory, reflex).
|
6 months
|
|
Health-related Quality of Life
Time Frame: 6 months
|
Difference between the treatment groups in changes in health-related quality of life as assessed by the EuroQol Five Dimensions questionnaire (EQ-5D-5L).
|
6 months
|
|
Hemoglobin A1c
Time Frame: 6 months
|
Difference between the treatment groups in the average percentage change from baseline in HbA1c levels.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: David Caraway, MD, Nevro Corp
Publications and helpful links
General Publications
- O'Connell NE, Ferraro MC, Gibson W, Rice AS, Vase L, Coyle D, Eccleston C. Implanted spinal neuromodulation interventions for chronic pain in adults. Cochrane Database Syst Rev. 2021 Dec 2;12:CD013756. doi: 10.1002/14651858.CD013756.pub2. Review.
- Petersen EA, Stauss TG, Scowcroft JA, Brooks ES, White JL, Sills SM, Amirdelfan K, Guirguis MN, Xu J, Yu C, Nairizi A, Patterson DG, Tsoulfas KC, Creamer MJ, Galan V, Bundschu RH, Mehta ND, Sayed D, Lad SP, DiBenedetto DJ, Sethi KA, Goree JH, Bennett MT, Harrison NJ, Israel AF, Chang P, Wu PW, Argoff CE, Nasr CE, Taylor RS, Caraway DL, Mekhail NA. High-Frequency 10-kHz Spinal Cord Stimulation Improves Health-Related Quality of Life in Patients With Refractory Painful Diabetic Neuropathy: 12-Month Results From a Randomized Controlled Trial. Mayo Clin Proc Innov Qual Outcomes. 2022 Jul 1;6(4):347-360. doi: 10.1016/j.mayocpiqo.2022.05.003. eCollection 2022 Aug.
- Petersen EA, Stauss TG, Scowcroft JA, Brooks ES, White JL, Sills SM, Amirdelfan K, Guirguis MN, Xu J, Yu C, Nairizi A, Patterson DG, Tsoulfas KC, Creamer MJ, Galan V, Bundschu RH, Mehta ND, Sayed D, Lad SP, DiBenedetto DJ, Sethi KA, Goree JH, Bennett MT, Harrison NJ, Israel AF, Chang P, Wu PW, Argoff CE, Nasr CE, Taylor RS, Caraway DL, Mekhail NA. Durability of High-Frequency 10-kHz Spinal Cord Stimulation for Patients With Painful Diabetic Neuropathy Refractory to Conventional Treatments: 12-Month Results From a Randomized Controlled Trial. Diabetes Care. 2022 Jan 1;45(1):e3-e6. doi: 10.2337/dc21-1813. No abstract available.
- Petersen EA, Stauss TG, Scowcroft JA, Brooks ES, White JL, Sills SM, Amirdelfan K, Guirguis MN, Xu J, Yu C, Nairizi A, Patterson DG, Tsoulfas KC, Creamer MJ, Galan V, Bundschu RH, Paul CA, Mehta ND, Choi H, Sayed D, Lad SP, DiBenedetto DJ, Sethi KA, Goree JH, Bennett MT, Harrison NJ, Israel AF, Chang P, Wu PW, Gekht G, Argoff CE, Nasr CE, Taylor RS, Subbaroyan J, Gliner BE, Caraway DL, Mekhail NA. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. 2021 Jun 1;78(6):687-698. doi: 10.1001/jamaneurol.2021.0538.
- Mekhail NA, Argoff CE, Taylor RS, Nasr C, Caraway DL, Gliner BE, Subbaroyan J, Brooks ES. High-frequency spinal cord stimulation at 10 kHz for the treatment of painful diabetic neuropathy: design of a multicenter, randomized controlled trial (SENZA-PDN). Trials. 2020 Jan 15;21(1):87. doi: 10.1186/s13063-019-4007-y.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CA2016-5
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Painful Diabetic Neuropathy
-
NCT07392619Not yet recruitingAcupressure | Painful Diabetic Peripheral Neuropathy (PDPN)
-
NCT04005287CompletedPeripheral Neuropathy | Painful Diabetic Neuropathy | Diabetic Neuropathies, Painful
-
NCT06495424Active, not recruitingPainful Diabetic Neuropathy | Peripheral Diabetic Neuropathy
-
NCT03066570CompletedPainful Diabetic Neuropathy | Diabetic Neuropathies, Painful | Neuralgia, Diabetic
-
NCT02427464CompletedDiabetic Neuropathy, Painful | Painful Diabetic Neuropathy
-
NCT04055090CompletedDiabetic Neuropathy, Painful | Painful Diabetic Neuropathy
-
NCT05118217Not yet recruitingDiabetic Peripheral Neuropathy | Painful Diabetic Neuropathy
-
NCT04678895RecruitingPainful Diabetic Neuropathy
-
NCT05476276CompletedPainful Diabetic Neuropathy
-
NCT04087941WithdrawnPainful Diabetic Neuropathy
Clinical Trials on Senza HF10 Therapy
-
NCT03470766TerminatedChronic Low Back Pain | Neuropathic Pain | Refractory Pain
-
NCT03680846Active, not recruiting
-
NCT02703818CompletedUpper Extremity Pain
-
NCT02385201Completed
-
NCT01017185CompletedMalignant Melanoma | Carcinoma of the Breast | Squamous Cell Carcinoma, Skin | Refractory Head and Neck Cancer
-
NCT04709757WithdrawnChronic Low-back Pain | Peripheral Neuropathy | CRPS
-
NCT02428036Completed
-
NCT02689375Unknown
-
NCT01653340Completed